Sugi Predict

Sugi Predict / Compounds / SCHEMBL3134608

SCHEMBL3134608

SCHEMBL3134608

O=C(O)CNCCNS(=O)(=O)c1cc2ccccc2s1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TPSAB1 Q15661 1/20 0.58
▸ MCL1 Q07820 1/20 0.47
▸ CA2 P00918 3/20 0.46
▸ HDAC1 Q13547 1/20 0.44
▸ DRD2 P14416 4/20 0.44
▸ HTR2A P28223 4/20 0.44
▸ HTR7 P34969 4/20 0.44
▸ HTR6 P50406 4/20 0.44
▸ ALDH1A1 P00352 1/20 0.42
▸ S1PR4 O95977 1/20 0.42
▸ S1PR5 Q9H228 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ CCR2 P41597 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ F10 P00742 1/20 0.40
▸ BCL2L1 Q07817 1/20 0.40
▸ CA1 P00915 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8798934 0.88 CA2 (0.51) TPSAB1MCL1CA2HDAC1DRD2
Hydrochloric Acid SCHEMBL6369828 0.77 TPSAB1 (0.61) TPSAB1MCL1CA2HDAC1DRD2
SCHEMBL3132766 0.76 CA1 (0.51) CA2ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL13595014 0.75 CA2 (0.56) TPSAB1MCL1CA2HDAC1DRD2
Hydrochloric Acid SCHEMBL6370510 0.73 TPSAB1 (0.98) TPSAB1CA2DRD2HTR2AHTR7
SCHEMBL4846244 0.72 MMP2 (0.46) CA2ALDH1A1CCR2
Hydrochloric Acid SCHEMBL6370150 0.71 TPSAB1 (0.64) TPSAB1MCL1CA2DRD2HTR2A
SCHEMBL5048183 0.71 HDAC1 (0.60) TPSAB1MCL1CA2HDAC1ALDH1A1
SCHEMBL9836719 0.71 CA2 (0.58) TPSAB1MCL1CA2HDAC1CCR2
SCHEMBL16756206 0.70 HDAC1 (0.62) TPSAB1MCL1CA2HDAC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2174936-B1 PNA monomer and precursor PANAGENE INC (KR) 2013-09-04 — — EP disclosed
EP-2174936-A1 PNA monomer and precursor Panagene, Inc. (KR) 2010-04-14 — — EP disclosed
EP-1501812-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-12-30 — — EP disclosed
US-7411065-B2 Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids PANAGENE, INC. (KR) 2008-08-12 — — US disclosed
US-7371860-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2008-05-13 — — US disclosed
US-7371859-B2 Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields PANAGENE, INC. (KR) 2008-05-13 — — US disclosed
CN-100347161-C PNA monomer and precursor PANAGENE INC (KR) 2007-11-07 — — CN disclosed
US-7179896-B2 Method of making PNA oligomers PANAGENE, INC. (KR) 2007-02-20 — — US disclosed
US-7145006-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2006-12-05 — — US disclosed
US-7125994-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2006-10-24 — — US disclosed
US-20060008835-A1 PNA monomer and precursor KIM SUNG K 2006-01-12 — — US disclosed
US-20060003374-A1 Method of making PNA oligomers KIM SUNG K 2006-01-05 — — US disclosed
US-20050283005-A1 PNA monomer and precursor KIM SUNG K 2005-12-22 — — US disclosed
US-6969766-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-29 — — US disclosed
US-20050250785-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 — — US disclosed
US-20050250786-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 — — US disclosed
CN-1659153-A PNA monomer and precursor PANAGENE INC (KR) 2005-08-24 — — CN disclosed
EP-1501812-A1 PNA MONOMER AND PRECURSOR Panagene, Inc. (KR) 2005-02-02 — — EP disclosed
US-20030225252-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2003-12-04 — — US disclosed
WO-2003091231-A1 PNA MONOMER AND PRECURSOR PANAGENE, INC. (US) 2003-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050283005-A1 PNA monomer and precursor PNISR, RNGTT, POLL TPSAB1 4003/4885MCL1 2507/4885CA2 3950/4885
US-20050250785-A1 PNA monomer and precursor PNISR, RNGTT, POLL TPSAB1 4003/4885MCL1 2507/4885CA2 3950/4885
US-20030225252-A1 PNA monomer and precursor PNISR, RNGTT, NCL TPSAB1 4522/4885MCL1 2038/4885CA2 3930/4885
US-20060008835-A1 PNA monomer and precursor PNISR, RNGTT, POLL TPSAB1 4003/4885MCL1 2507/4885CA2 3950/4885
US-20050250786-A1 PNA monomer and precursor PNISR, RNGTT, NPR1 TPSAB1 3984/4885MCL1 3072/4885CA2 3782/4885
US-20060003374-A1 Method of making PNA oligomers RNGTT, POLL, PNISR TPSAB1 4152/4885MCL1 3127/4885CA2 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.